Sun Pharmaceutical Industries Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Dilip Shanghvi
Chief executive officer
₹60.5m
Total compensation
CEO salary percentage | 75.6% |
CEO tenure | 31.8yrs |
CEO ownership | 9.6% |
Management average tenure | 2.9yrs |
Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | ₹111b |
Jun 30 2024 | n/a | n/a | ₹104b |
Mar 31 2024 | ₹61m | ₹46m | ₹96b |
Dec 31 2023 | n/a | n/a | ₹89b |
Sep 30 2023 | n/a | n/a | ₹85b |
Jun 30 2023 | n/a | n/a | ₹84b |
Mar 31 2023 | ₹55m | ₹41m | ₹85b |
Dec 31 2022 | n/a | n/a | ₹42b |
Sep 30 2022 | n/a | n/a | ₹41b |
Jun 30 2022 | n/a | n/a | ₹39b |
Mar 31 2022 | ₹51m | ₹38m | ₹33b |
Dec 31 2021 | n/a | n/a | ₹64b |
Sep 30 2021 | n/a | n/a | ₹62b |
Jun 30 2021 | n/a | n/a | ₹60b |
Mar 31 2021 | ₹46m | ₹35m | ₹29b |
Dec 31 2020 | n/a | n/a | ₹24b |
Sep 30 2020 | n/a | n/a | ₹15b |
Jun 30 2020 | n/a | n/a | ₹7b |
Mar 31 2020 | ₹43m | ₹32m | ₹38b |
Dec 31 2019 | n/a | n/a | ₹40b |
Sep 30 2019 | n/a | n/a | ₹43b |
Jun 30 2019 | n/a | n/a | ₹30b |
Mar 31 2019 | ₹263k | ₹1 | ₹27b |
Dec 31 2018 | n/a | n/a | ₹34b |
Sep 30 2018 | n/a | n/a | ₹24b |
Jun 30 2018 | n/a | n/a | ₹36b |
Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensation vs Market: Dilip's total compensation ($USD708.95K) is below average for companies of similar size in the Indian market ($USD1.05M).
Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.
CEO
Dilip Shanghvi (69 yo)
31.8yrs
Tenure
₹60,541,920
Compensation
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 419.1b | |
Executive VP | no data | ₹68.75m | 0.12% ₹ 5.2b | |
Chief Financial Officer | 7.5yrs | ₹38.89m | no data | |
Executive Vice-President of Global Operations | no data | no data | no data | |
EVP & Chief Information Officer | less than a year | no data | no data | |
VP, Head of Investor Relations & Strategic Projects | no data | no data | no data | |
Company Secretary & Compliance Officer | 2.9yrs | no data | no data | |
Director of Corporate Development | no data | ₹65.30m | no data | |
Chief Human Resources Officer | less than a year | no data | no data | |
Head of India Business | no data | no data | no data | |
Chief Executive Officer of North America Business | 8.3yrs | no data | no data | |
Head of Corporate Relations & CSR - India Regulatory Affairs | no data | no data | no data |
2.9yrs
Average Tenure
60yo
Average Age
Experienced Management: SUNPHARMA's management team is considered experienced (2.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD & Chairman of the Board | 31.8yrs | ₹60.54m | 9.6% ₹ 419.1b | |
Executive VP | 1.5yrs | ₹68.75m | 0.12% ₹ 5.2b | |
Non-Executive & Non-Independent Director | 30.9yrs | ₹2.20m | 1.8% ₹ 78.5b | |
Non-Executive & Independent Director | 3.6yrs | ₹5.10m | no data | |
Non-Executive Independent Director | 6.6yrs | ₹7.80m | no data | |
Independent Director | 1.5yrs | ₹3.20m | no data | |
Lead Independent Director | 3.6yrs | ₹8.50m | no data | |
Independent Director | 2.1yrs | ₹4.80m | no data |
3.6yrs
Average Tenure
67.5yo
Average Age
Experienced Board: SUNPHARMA's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 19:54 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sun Pharmaceutical Industries Limited is covered by 73 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nitin Bhasin | Ambit Capital |
Prashant Nair | Ambit Capital |
null null | Anand Rathi Shares and Stock Brokers Limited |